Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
about
Role of HLA Adaptation in HIV EvolutionInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionProfiling immunity to HIV vaccines with systems biologyProgress and prospects: immune responses to viral vectorsIL-33 induces nuocytes and modulates liver injury in viral hepatitis.Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccinationPre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humansVaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionalityAdenoviral vectors as novel vaccines for influenza.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers.Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.HIV-1 vaccine development after STEP.Novel directions in HIV-1 vaccines revealed from clinical trialsMucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.Novel adenovirus vector-based vaccines for HIV-1.New approaches to design HIV-1 T-cell vaccinesOverview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineNovel vaccine vectors for HIV-1.Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.Lessons drawn from recent HIV vaccine efficacy trials.Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humansDNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.A Novel High-Throughput Screening Assay to Identify Inhibitors of HIV-1 gp120 Protein Interaction with DC-SIGN.Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccineOptimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccineHIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step studyRhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Risk of immunodeficiency virus infection may increase with vaccine-induced immune response.Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).DNA-based HIV vaccines do not induce generalized activation in mucosal tissue T cells.
P2860
Q26772713-59216D79-D89F-4965-8256-E5CE82E8FF6AQ27001897-8DEB7C65-734F-4E0A-989A-8581ECE36EB8Q27010629-9A02736B-E926-4C3D-8D44-4EC6C6673BA5Q28264531-DFB694F1-DC8E-4EFA-9EF8-A4EF8A8E6F1CQ28588039-4E664F43-A0F6-4394-974E-9134E4C81211Q28730757-4B2A0BEE-989A-4499-9291-DF59EFEC4C68Q28741103-9A862996-5C1F-4AEF-BE7A-05C66E303017Q28744027-98E45F8F-2D95-4FB3-B095-D683BB14AE85Q30370445-B0F93334-533F-472E-9AE2-1951A19CF73AQ30382097-5485CD0A-8E84-4B22-8893-A0B37A7E0E96Q33565035-27C1CAC3-3B06-4600-B5B4-4B909EC61F2FQ33601808-B218A5CE-AA59-4272-AB4D-29E405834F39Q33642318-33FF53E8-F46F-4AA9-B760-D406F5A8E593Q33645528-4AC75A2C-9621-41C8-86ED-0A6AA1FBA85AQ34120780-A55B61D8-3D16-4EBD-AFA7-008CC9EE9001Q34178208-37825D0C-DE7E-4C85-A799-12F31CBCBEAEQ34257640-6FCE56FC-FA22-4627-9F5C-7EC61695718CQ34274849-96F30BB3-8057-4F29-9D2B-B517A81CB3C1Q34373275-84F63748-9609-4777-9217-77B82D3C6A12Q34541191-E28DFBF9-7409-43D2-A48F-5BA855BAAFE9Q34673391-A28305DC-1C17-44D3-BD69-B128604D1920Q34789269-3657FA1D-22C5-4B91-9BC5-BC227DA4295BQ34816639-851CDBAF-310A-4779-A1DD-20C1B936DB58Q35055188-28B6BEF3-9A66-4BE2-912C-17643D666B31Q35382338-AD0B3E21-D69A-4388-8D94-30DB39AFC9F0Q35553053-EC1EA1FE-208E-4AFF-844E-FE431F73ECD3Q35640645-5BA69B2B-03A6-4E87-B5B7-13BDE5DB6B38Q35666180-FDE73112-D4D4-433A-A8D0-71EFC0395754Q35709133-85D1E136-0D8F-4375-B80B-FFF5A7F89902Q35745815-356EF95B-73CE-411F-810C-7FC95F0AAB48Q35980530-ECDB55BF-B45B-4E3D-A415-95FE58C80707Q36009232-6C68F1FC-4044-4B9A-9EAE-3A7F56BA0C38Q36084253-3E14A6A4-96DC-409C-A842-C0AF2BC2B604Q36145561-B4D99B5D-7BD6-42C8-9171-FA2A8820B696Q36154059-9F867485-7645-408D-901B-0BB2A5A57FD9Q36276187-753E7DDA-6B04-44AB-AA2A-5975E95F70F7Q36276637-3119D6A7-DCCA-4612-81FE-ED82FAF386B5Q36483435-9D6BF13A-51A6-4A60-8BE7-F122BFA95CCDQ36495587-E9C6A828-9190-4D5E-A41A-75BB9E1093D9Q36694851-5E248A78-32DB-4592-9FFD-A4C6CC48DC26
P2860
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@en
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@nl
type
label
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@en
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@nl
prefLabel
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@en
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@nl
P2093
P2860
P921
P356
P1433
P1476
Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.
@en
P2093
Dan H Barouch
Danilo R Casimiro
Jinyan Liu
Joern E Schmitz
John W Shiver
Kara L O'Brien
Michael N Robertson
Michael R Betts
Michelle A Lifton
Natalie A Hutnick
P2860
P2888
P304
P356
10.1038/NM.1991
P407
P577
2009-07-20T00:00:00Z